Propolis-plus
Food supplement declared in France, decision dated 23 October 2026
Propolis-plus, from SENTIER NATURE, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: propolis 480 mg per day, Thymus vulgaris 420 mg per day, Echinacea purpurea 420 mg per day. None of the rules we check flags an issue with its declared composition.
- Brand
- not provided
- Food business operator placing the product on the market
- SENTIER NATURE
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 6
- Directions for use
- 1 à 2 gélules 3 fois par jour avec un verre d'eau
- Intended populations
- General population
- Not recommended (according to the manufacturer)
- Breastfeeding women, Children (under 12), Pregnant women
- Objectives stated by the manufacturer (these are not authorised claims)
- Immunity
Declaration 380200, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Thymus vulgaris L. | Feuille | Poudre (de plantes séchées ou broyées) | 420 mg |
| Echinacea purpurea (L.) Moench | Racine | Poudre (de plantes séchées ou broyées) | 420 mg |
Substances
| Name | Per day |
|---|---|
| propolis | 480 mg |
Additives
E410, E1204
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Déconseillé en cas de pathologie du système immunitaire ou de prise de médicaments affectant le système immunitaire
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Thymus vulgaris L.
Read the warning, when it applies and the studies cited
THYME - THYMUS VULGARIS - Buccal
Route of administration: Buccal (Mills and Bone 2005; Blumenthal et al. 2000)
Cautions and warnings
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Health Canada monograph dated 28 March 2025
THYME - THYMUS VULGARIS - Oral
Route of administration: Oral (Mills and Bone 2005; Blumenthal et al. 2000)
Cautions and warnings
Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant.
Health Canada monograph dated 26 June 2026
THYME - THYMUS VULGARIS - Topical
Route of administration: Topical (Mills and Bone 2005; Blumenthal et al. 2000)
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
- Echinacea purpurea (L.) Moench
Read the warning, when it applies and the studies cited
ECHINACEA - ECHINACEA PURPUREA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a progressive systemic disease such as tuberculosis, collagenosis, multiple sclerosis, or an immune system disorder (EMA 2015; Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2015: European Medicines Agency (GB). EMA/HMPC/48704/2014. European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens. Final. [Accessed 2024 December 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications to suppress the immune system (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Known adverse reactions
Condition of application: Preparations containing herb top.
Stop use if hypersensitivity/allergy occurs (MHRA 2018; EMA 2015; Kligler 2003; WHO 1999).
Sources cited by Health Canada (5)
- EMA 2015: European Medicines Agency (GB). EMA/HMPC/48704/2014. European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens. Final. [Accessed 2024 December 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf
- Kligler B. 2003. Echinacea. American Family Physician 67(1):77-80. [Accessed 2024 February 22]. Available from: http://www.aafp.org/afp/2003/0101/p77.html
- MHRA 2018: Medicines and Healthcare products Regulatory Agency (GB). Press release: Echinacea herbal products should not be used in children under 12 years old. [Accessed 2024 December 11]. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20140208035927/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON180627
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Geneva (CHE) : Organisation mondiale de la santé; 1999.
- propolis
Read the warning, when it applies and the studies cited
PROPOLIS - Oral
Cautions and warnings
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).
Sources cited by Health Canada (5)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
- Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
- Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
- Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed
Condition of application: Relief of sore throat/mouth and throat infections.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).
Sources cited by Health Canada (9)
- Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
- Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
- Machackova J. The incidence of allergy to propolis in 605 consecutive patients patch tested in Prague. Contact Dermatitis 1988;18:210-212. PubMed
- Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
- PPRC 2020: Pharmacopoeia of the People's Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.
- Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
- Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
- Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
- Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed
Health Canada monograph dated 30 May 2025
PROPOLIS Buccal
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).
Sources cited by Health Canada (5)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
- Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
- Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
- Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products, except those not swallowed (e.g., gargles, rinses).
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).
Sources cited by Health Canada (8)
- Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
- Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
- Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
- PPRC 2020: Pharmacopoeia of the People’s Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People’s Republic of China; 2020.
- Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
- Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
- Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
- Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- PRÓPOLIS PLUS Obire® in your life, declared in 2025 : different composition: 5 ingredient(s) added, 2 missing
- PRÓPOLIS PLUS LABORATORIOS BIO-DIS PHARMA S.L, declared in 2025 : different composition: 5 ingredient(s) added, 2 missing
- PROPOLIS PLUS® Obire® in your life, declared in 2022 : different composition: 5 ingredient(s) added, 2 missing
- PROPOLIS-PLUS SENTIER NATURE, declared in 2018, earlier declaration, replaced by the 2026 declaration : different composition: 2 ingredient(s) added, 2 missing
- PROPOLIS-PLUS SENTIER NATURE, earlier declaration, replaced by the 2026 declaration : different composition: 1 ingredient(s) added, 1 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Propolis-plus: composition and regulation”, https://compoatlas.com/en/supplements/products/380200-propolis-plus, updated 15 November 2026.